Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Grand Pharma Forms JV with HuangShi Feiyun Pharma

publication date: Feb 25, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China Grand Pharmaceutical and Healthcare will form a JV with HuangShi Feiyun Pharma that will be capitalized with $20 million. China Grand Pharma will contribute $12 million while HuangShi Feiyun will purchase the remaining 40% with $8 million. HuangShi Feiyun is an oncology drug and anti-viral medicines company located in Hubei Province. Its products will be the basis of the new JV and will serve to expand China Grand Pharma’s portfolio. More details....

Stock Symbol: (HK: 00512)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors